Linezolid: Its role in the treatment of gram-positive, drug-resistant bacterial infections

Paul W. Ament, Namirah Jamshed, John P. Horne

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

While the choices available for the management of gram-positive, drug-resistant bacterial infections are becoming limited, antimicrobial resistance is becoming increasingly problematic because of the widespread overuse of antibiotics. Linezolid is a synthetic antibiotic belonging to a new class of antimicrobials called the oxazolidinones. Linezolid disrupts bacterial growth by inhibiting the initiation process of protein synthesis - a mechanism of action that is unique to this class of drugs. It is well absorbed with high bioavailability that allows conversion to oral therapy as soon as the patient is clinically stable. It has been approved for certain gram-positive infections including certain drug-resistant enterococcus, staphylococcus, and pneumococcus strains. It is generally well tolerated, with myelosuppression being the most serious adverse effect. As a non-selective inhibitor of monoamine oxidase, caution is recommended when used with adrenergic or serotonergic agents (e.g., tyramine, dopamine, pseudoephedrine, and selective serotonin reuptake inhibitors). Judicious use of this medication should help physicians treat patients with multidrug-resistant infections. Copyright

Original languageEnglish (US)
Pages (from-to)663-670
Number of pages8
JournalAmerican Family Physician
Volume65
Issue number4
StatePublished - Feb 15 2002

Fingerprint

Linezolid
Bacterial Infections
Pseudoephedrine
Pharmaceutical Preparations
Oxazolidinones
Anti-Bacterial Agents
Serotonin Agents
Tyramine
Monoamine Oxidase Inhibitors
Enterococcus
Serotonin Uptake Inhibitors
Streptococcus pneumoniae
Infection
Staphylococcus
Adrenergic Agents
Biological Availability
Dopamine
Therapeutics
Physicians
Growth

ASJC Scopus subject areas

  • Family Practice

Cite this

Linezolid : Its role in the treatment of gram-positive, drug-resistant bacterial infections. / Ament, Paul W.; Jamshed, Namirah; Horne, John P.

In: American Family Physician, Vol. 65, No. 4, 15.02.2002, p. 663-670.

Research output: Contribution to journalArticle

@article{1c3b5cec99744e1c88b934ef49645b28,
title = "Linezolid: Its role in the treatment of gram-positive, drug-resistant bacterial infections",
abstract = "While the choices available for the management of gram-positive, drug-resistant bacterial infections are becoming limited, antimicrobial resistance is becoming increasingly problematic because of the widespread overuse of antibiotics. Linezolid is a synthetic antibiotic belonging to a new class of antimicrobials called the oxazolidinones. Linezolid disrupts bacterial growth by inhibiting the initiation process of protein synthesis - a mechanism of action that is unique to this class of drugs. It is well absorbed with high bioavailability that allows conversion to oral therapy as soon as the patient is clinically stable. It has been approved for certain gram-positive infections including certain drug-resistant enterococcus, staphylococcus, and pneumococcus strains. It is generally well tolerated, with myelosuppression being the most serious adverse effect. As a non-selective inhibitor of monoamine oxidase, caution is recommended when used with adrenergic or serotonergic agents (e.g., tyramine, dopamine, pseudoephedrine, and selective serotonin reuptake inhibitors). Judicious use of this medication should help physicians treat patients with multidrug-resistant infections. Copyright",
author = "Ament, {Paul W.} and Namirah Jamshed and Horne, {John P.}",
year = "2002",
month = "2",
day = "15",
language = "English (US)",
volume = "65",
pages = "663--670",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "4",

}

TY - JOUR

T1 - Linezolid

T2 - Its role in the treatment of gram-positive, drug-resistant bacterial infections

AU - Ament, Paul W.

AU - Jamshed, Namirah

AU - Horne, John P.

PY - 2002/2/15

Y1 - 2002/2/15

N2 - While the choices available for the management of gram-positive, drug-resistant bacterial infections are becoming limited, antimicrobial resistance is becoming increasingly problematic because of the widespread overuse of antibiotics. Linezolid is a synthetic antibiotic belonging to a new class of antimicrobials called the oxazolidinones. Linezolid disrupts bacterial growth by inhibiting the initiation process of protein synthesis - a mechanism of action that is unique to this class of drugs. It is well absorbed with high bioavailability that allows conversion to oral therapy as soon as the patient is clinically stable. It has been approved for certain gram-positive infections including certain drug-resistant enterococcus, staphylococcus, and pneumococcus strains. It is generally well tolerated, with myelosuppression being the most serious adverse effect. As a non-selective inhibitor of monoamine oxidase, caution is recommended when used with adrenergic or serotonergic agents (e.g., tyramine, dopamine, pseudoephedrine, and selective serotonin reuptake inhibitors). Judicious use of this medication should help physicians treat patients with multidrug-resistant infections. Copyright

AB - While the choices available for the management of gram-positive, drug-resistant bacterial infections are becoming limited, antimicrobial resistance is becoming increasingly problematic because of the widespread overuse of antibiotics. Linezolid is a synthetic antibiotic belonging to a new class of antimicrobials called the oxazolidinones. Linezolid disrupts bacterial growth by inhibiting the initiation process of protein synthesis - a mechanism of action that is unique to this class of drugs. It is well absorbed with high bioavailability that allows conversion to oral therapy as soon as the patient is clinically stable. It has been approved for certain gram-positive infections including certain drug-resistant enterococcus, staphylococcus, and pneumococcus strains. It is generally well tolerated, with myelosuppression being the most serious adverse effect. As a non-selective inhibitor of monoamine oxidase, caution is recommended when used with adrenergic or serotonergic agents (e.g., tyramine, dopamine, pseudoephedrine, and selective serotonin reuptake inhibitors). Judicious use of this medication should help physicians treat patients with multidrug-resistant infections. Copyright

UR - http://www.scopus.com/inward/record.url?scp=0037084298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037084298&partnerID=8YFLogxK

M3 - Article

C2 - 11871684

AN - SCOPUS:0037084298

VL - 65

SP - 663

EP - 670

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 4

ER -